iHateHospitals.com

MEDICAL NEWS:
Abstract

Background  Physicians, influenced by various pressures, may document information in patient records that they did not personally observe.

Objective  To evaluate the hospital chart documentation practices of internists and internal medicine sub-specialists in the Northeastern
United States.

Design  An anoNY (New York)mous mail survey questionnaire.

Participants  One thousand one hundred twenty-six randomly selected internists and internal medicine sub-specialists.
[...]

CANCER NEWS: Not all doctors email patients, nor for that matter do all doctors email each other - but I have found it to be helpful for many patients. Not all patients have my email account, but for some patients for whom it seems appropriate I have given out my office email adDr. [...]

CANCER NEWS: IntroductionPatients with primary operable estrogen receptor negative (ER-) breast (women’s) cancer account for approximately 30% of all cases and generally have worse prognosis (outlook) than ER+ patients. Nevertheless, a significant proportion of ER- cases have favourable outcome and could potentially benefit from a less aggressive course of therapy. Identification of such good [...]

CANCER NEWS: COPENHAGEN, Denmark — Genmab has announced plans to begin four studies of ofatumumab in chronic lymphocytic leukemia and non-Hodgkin’s lymphoma. Genmab A/S announced today plans to begin four studies of ofatumumab in chronic lymphocytic leukemia (CLL) and follicular non-Hodgkin’s lymphoma (NHL) this year. “Genmab and GSK have worked diligently to expand the [...]

CANCER NEWS: NORWALK, Conn. — The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a clinical trial with the oral immunomodulatory agent pomalidomide (CC-4047) in patients who have received at least two prior therapies including treatments with REVLIMID(R) (lenalidomide) and VELCADE(R) (bortezomib) for Injection. Paul Richardson, MD, Clinical Director of the Jerome [...]

CANCER NEWS: Micromet, Inc., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, announced publication of a Phase 1 clinical study(1) on its BiTE(R) antibody blinatumomab (MT103/MEDI-538) in this week’s issue of Science. The article is available at www.sciencemag.org. Blinatumomab is being co-developed with MedImmune. Blinatumomab is [...]

CANCER NEWS: According to a study from the United States, “Metastatic disease is present in up to 20% of patients at the time of diagnosis (finding out what’s wrong) of colorectal cancer. The most frequently involved sites are the liver and the lungs.A rare form of lung metastatic disease is endobronchial metastases, most commonly [...]

CANCER NEWS: Stem cell scientists in the region have helped to develop a more accurate way of identifying aggressive forms of bowel cancer, which should eventually lead to better treatment and improved survival rates. The UK-led team, headed by scientists from Durham University and the North-East England Stem Cell Institute, (NESCI), studied tissue samples [...]

CANCER NEWS: According to a study from the United States, “Metastatic disease is present in up to 20% of patients at the time of diagnosis (finding out what’s wrong) of colorectal cancer. The most frequently involved sites are the liver and the lungs.A rare form of lung metastatic disease is endobronchial metastases, most commonly [...]

MEDICAL NEWS: Partial verification refers to the situation where a subset of patients is not verified by the reference (gold) standard and is excluded from the analysis. If partial verification is present, the observed (naive) measures of accuracy such as sensitivity and specificity are most likely to be biased. Recently, Harel and Zhou showed [...]

MEDICAL NEWS: Partial verification refers to the situation where a subset of patients is not verified by the reference (gold) standard and is excluded from the analysis. If partial verification is present, the observed (naive) measures of accuracy such as sensitivity and specificity are most likely to be biased. Recently, Harel and Zhou showed [...]

(Mesothelioma News) ROCKVILLE, Md. — Human Genome Sciences, Inc. today announced that it has completed the enrollment and initial dosing of patients in a randomized Phase 2 trial of HGS-ETR1 (mapatumumab) in combination with the chemotherapy (serious, serious drugs) agents paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC). “There is [...]